Objectives: to study the oculo- hypotensive effect of non-selective phosphodiestrase inhibitor aminophylline. Methods: The study was conducted on fifteen albino rabbits (2.5–2.8 Kg) and model of acute ocular hypertension was obtained by 5% glucose water administration at 15ml/kg through the marginal vein of the rabbit’s ear. Aminophylline was dissolved in vehicle of phosphate buffer saline and diluted to desired concentration as 0.5%. Phosphate buffer saline solution also served as control. The left eye of rabbit was received one drop of aminophylline (0.5%) on the other hand the right eye treated by the vehicle and considered as control parameter. The pressure measurement was recorded at 15, 30, 45, 60, 90, 120, 135, 150 and 165 min after drug instillation. Results: After 30 minutes of topical 0.5% aminophylline administration the normal tension of the eye remain unchanged. However topical 0.5% aminophylline eye drop significantly (p < 0.05) successes in the decrease of the acute elevation of ocular pressure due to 5% glucose infusion. Moreover, in this study aminophylline pretreatment has the ability to facilitating the returns of the IOP to normal levels Conclusions: Topical administration of aminophylline (0.5%) significantly prevent acute rise in the ocular pressure induced by 5% glucose administration. The IOP lowering effect of aminophylline can be considered as potential antiglaucoma drug.
Hypertrophic scars are pathological scars which result from exaggerated skin proliferation following a wound and injury. Although many theories have been implicated for keloidogenesis, the precise pathophysiological cause is still masked. Different treatment strategies have been tried in their management, but there is no satisfactory option for treating hypertrophic scar currently; moreover the standard steroid therapy is associated with numerous local side effects, and there is a need for researches in new treatment options. The aim of this study is to evaluate the role of topical isoxsuprine in experimentally induced hypertrophic scar in rabbits. In the current experimental study, 40 healthy male albino rabbits between 12 and 14 months of age were studied. These rabbits were categorized into five groups: healthy animal group (n = 8), hypertrophic scar without treatment (n = 8), hypertrophic scar treated with triamcinolone acetonide gel (n = 8), and hypertrophic scar treated with isoxsuprine gel (n = 8). Histological assessment of skin biopsy, including the conventional hematoxylin and eosin stain, and immunohistochemistry for transforming the growth factor beta 1 level (TGF-β1) and collagen 3 alpha1 (COLIIIαI) in skin tissue was done. The immunohistochemical score of TGF-β and collagen III was highest in group 2 (hypertrophic scar without treatment), followed by group 3 (hypertrophic scar treated with triamcinolone acetonide gel) and group 4 (hypertrophic scar treated with isoxsuprine gel) -no significant difference between them since p > 0.05, and then by group 1 (healthy control group). Regarding histopathological scores of inflammation, the scar height, and scar index, the scores were highest in was highest in group 2 (hypertrophic scar without treatment), followed by group 3 (hypertrophic scar treated with triamcinolone acetonide gel) and group 4 (hypertrophic scar treated with isoxsuprine gel) -no significant difference between them since p > 0.05,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.